platoseedplatoseed
A therapeutics platform for curing inflammatory disorders
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
Promakhos Therapeutics is developing transformative medicines aimed at restoring the body's natural ability to manage inflammation, rather than broadly suppressing the immune system, with a focus on inflammatory diseases. Founded in 2021 and based in Boston, it leverages patient-derived insights to address root causes of inflammation.
The company develops therapies that restore immune balance to control inflammation and promote healing, using patient sample insights to target root causes rather than immune suppression. Their approach centers on immunomodulatory medicines designed to reestablish the body's natural inflammatory regulation and healing processes.
Who it’s for: Biotech/pharma stakeholders pursuing immunology-based therapies for inflammatory diseases; pharmaceutical researchers and translational science teams; potential biopharma partners interested in novel immunomodulatory platforms.
Founded 2021; team and leadership details provided; no explicit funding or hiring announcements in the provided text
I believe we can discover unexpected things that can transform our lives. I have lived and performed research in 4 countries and 2 continents. Previously I was a postdoc at Harvard. I founded Promakhos because I think we have given to “autoimmune” diseases a grossly misleading name and we treat them in a primitive way. Promakhos means the first to enter a battle. In ancient Greece Promakhos was the strongest to put in the front line of an army so that they will not even have to start a battle.
CSO and co-founder of Promakhos. In high school, Jasper built a web-shop. He obtained a BSc, MSc and PhD in Biomedical Sciences from KU Leuven. He pioneered the use of XPO1 inhibitors for treating cancer and invented a CRISPR-directed evolution technology for drug target deconvolution. Jasper then joined the Dana-Farber Cancer Institute & Broad Institute of MIT and Harvard to identify and validate new drug targets for gastrointestinal cancers. Now, he develops drugs for chronic inflammation.
Using the immune system to cure disease
Multi-targeted therapeutics to treat complex diseases
